Juniper Pharmaceuticals Inc (NASDAQ:JNP) reached a new 52-week high on Wednesday . The stock traded as high as $11.50 and last traded at $11.45, with a volume of 64930 shares traded. The stock had previously closed at $11.00.

Several equities research analysts have recently weighed in on the stock. Roth Capital upped their target price on shares of Juniper Pharmaceuticals from $12.00 to $24.00 and gave the stock a “buy” rating in a report on Friday, March 9th. ValuEngine lowered shares of Juniper Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, December 1st. Finally, TheStreet raised shares of Juniper Pharmaceuticals from a “c+” rating to a “b-” rating in a report on Monday. Two investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company. The stock has an average rating of “Buy” and an average price target of $29.00.

How to Become a New Pot Stock Millionaire

The company has a quick ratio of 1.68, a current ratio of 2.00 and a debt-to-equity ratio of 0.08. The firm has a market capitalization of $119.29, a price-to-earnings ratio of -73.33 and a beta of 0.58.

Juniper Pharmaceuticals (NASDAQ:JNP) last issued its quarterly earnings data on Thursday, March 8th. The specialty pharmaceutical company reported $0.11 EPS for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.22. Juniper Pharmaceuticals had a negative net margin of 4.12% and a negative return on equity of 3.95%. The firm had revenue of $11.79 million for the quarter, compared to analyst estimates of $16.00 million. research analysts forecast that Juniper Pharmaceuticals Inc will post 3.5 EPS for the current year.

A number of large investors have recently modified their holdings of JNP. Municipal Employees Retirement System of Michigan boosted its stake in shares of Juniper Pharmaceuticals by 26.1% in the 4th quarter. Municipal Employees Retirement System of Michigan now owns 297,600 shares of the specialty pharmaceutical company’s stock valued at $1,443,000 after purchasing an additional 61,560 shares during the last quarter. Macquarie Group Ltd. lifted its stake in Juniper Pharmaceuticals by 21.7% in the fourth quarter. Macquarie Group Ltd. now owns 34,585 shares of the specialty pharmaceutical company’s stock valued at $168,000 after buying an additional 6,166 shares during the period. Deutsche Bank AG lifted its stake in Juniper Pharmaceuticals by 112.1% in the fourth quarter. Deutsche Bank AG now owns 37,181 shares of the specialty pharmaceutical company’s stock valued at $180,000 after buying an additional 19,653 shares during the period. Renaissance Technologies LLC lifted its stake in Juniper Pharmaceuticals by 19.3% in the fourth quarter. Renaissance Technologies LLC now owns 537,450 shares of the specialty pharmaceutical company’s stock valued at $2,607,000 after buying an additional 86,800 shares during the period. Finally, Bailard Inc. acquired a new position in Juniper Pharmaceuticals in the fourth quarter valued at approximately $267,000. 39.67% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: “Juniper Pharmaceuticals (JNP) Hits New 1-Year High at $11.50” was reported by Daily Political and is the property of of Daily Political. If you are accessing this article on another publication, it was copied illegally and republished in violation of US and international copyright and trademark legislation. The legal version of this article can be viewed at https://www.dailypolitical.com/2018/03/14/juniper-pharmaceuticals-jnp-hits-new-1-year-high-at-11-50.html.

About Juniper Pharmaceuticals

Juniper Pharmaceuticals, Inc is a women’s health therapeutics company. The Company is focused on developing therapeutics that address unmet medical needs in women’s health. It operates in two segments: product and service. The product segment is engaged in manufacturing and supplying CRINONE, the Company’s commercialized product.

Receive News & Ratings for Juniper Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juniper Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.